Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 14/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.78 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400624 | 1.00 | TRPA1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11NFE2L2 | |
| SCHEMBL3400635 | 1.00 | TRPA1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11NFE2L2 | |
| A-226 SCHEMBL3405855 | 0.88 | SIGMAR1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11HTT | |
| A-226 SCHEMBL4455484 | 0.88 | SIGMAR1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11HTT | |
| A-226 SCHEMBL3405856 | 0.88 | SIGMAR1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11HTT | |
| SCHEMBL4455463 | 0.87 | TRPA1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11 | |
| SCHEMBL4455471 | 0.87 | TRPA1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11 | |
| SCHEMBL4455468 | 0.87 | TRPA1 (1.00) | TRPA1SIGMAR1GABRA1ABCB11 | |
| SCHEMBL4447574 | 0.84 | TRPA1 (0.72) | TRPA1SIGMAR1GABRA1ABCB11 | |
| SCHEMBL4447576 | 0.84 | TRPA1 (0.72) | TRPA1SIGMAR1GABRA1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108905-B2 | TRPA1 antagonists | ABBVIE INC. (US) | 2015-08-18 | — | — | US | claimed |
| US-20090176883-A1 | TRPA1 Antagonists | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | claimed |
| US-9108905-B2 | TRPA1 antagonists | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2249820-A1 | TRPA1 ANTAGONISTS | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089082-A1 | TRPA1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176883-A1 | TRPA1 Antagonists | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176883-A1 | TRPA1 Antagonists | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885SIGMAR1 303/4885GABRA1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.